Sign In

Login

Password

Forgot Password ? Sign Up

Trovafloxacin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trovafloxacin" in English language version.

refsWebsite
Global rank English rank
5doi.org
2nd place
2nd place
5nih.gov
4th place
4th place
3washingtonpost.com
34th place
27th place
2semanticscholar.org
11th place
8th place
2nytimes.com
7th place
7th place
1fda.gov
447th place
338th place
1europa.eu
68th place
117th place
1sagepub.com
731st place
638th place
1theguardian.com
12th place
11th place

doi.org

  • Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, et al. (December 1996). "Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro". Antimicrobial Agents and Chemotherapy. 40 (12): 2691–2697. doi:10.1128/AAC.40.12.2691. PMC 163605. PMID 9124824.
  • Pannu HK, Gottlieb L, Fishman EK (2001). "Acute liver failure due to trovafloxacin: CT findings". Emergency Radiology. 8 (2): 108–110. doi:10.1007/PL00011876. S2CID 43307678.
  • Oldani M (2016). "Trovafloxacin (Trovan) Controversy". The SAGE Encyclopedia of Pharmacology and Society. SAGE Publications, Inc. pp. 1444–1447. doi:10.4135/9781483349985.n409. ISBN 9781483350004. Retrieved 2019-01-21.
  • Williams D, Hopkins S (June 1998). "Safety of trovafloxacin in treatment of lower respiratory tract infections". European Journal of Clinical Microbiology & Infectious Diseases. 17 (6): 454–458. doi:10.1007/bf01691582. PMID 9758292. S2CID 1325773.
  • Lipsky BA, Baker CA (February 1999). "Fluoroquinolone toxicity profiles: a review focusing on newer agents". Clinical Infectious Diseases. 28 (2): 352–364. doi:10.1086/515104. PMID 10064255.

europa.eu

ema.europa.eu

fda.gov

accessdata.fda.gov

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, et al. (December 1996). "Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro". Antimicrobial Agents and Chemotherapy. 40 (12): 2691–2697. doi:10.1128/AAC.40.12.2691. PMC 163605. PMID 9124824.
  • Williams D, Hopkins S (June 1998). "Safety of trovafloxacin in treatment of lower respiratory tract infections". European Journal of Clinical Microbiology & Infectious Diseases. 17 (6): 454–458. doi:10.1007/bf01691582. PMID 9758292. S2CID 1325773.
  • Lipsky BA, Baker CA (February 1999). "Fluoroquinolone toxicity profiles: a review focusing on newer agents". Clinical Infectious Diseases. 28 (2): 352–364. doi:10.1086/515104. PMID 10064255.
  • Sabatini C, Bosis S, Semino M, Senatore L, Principi N, Esposito S (June 2012). "Clinical presentation of meningococcal disease in childhood". Journal of Preventive Medicine and Hygiene. 53 (2): 116–119. PMID 23240173.

ncbi.nlm.nih.gov

  • Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, et al. (December 1996). "Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro". Antimicrobial Agents and Chemotherapy. 40 (12): 2691–2697. doi:10.1128/AAC.40.12.2691. PMC 163605. PMID 9124824.

nytimes.com

sagepub.com

sk.sagepub.com

semanticscholar.org

api.semanticscholar.org

  • Pannu HK, Gottlieb L, Fishman EK (2001). "Acute liver failure due to trovafloxacin: CT findings". Emergency Radiology. 8 (2): 108–110. doi:10.1007/PL00011876. S2CID 43307678.
  • Williams D, Hopkins S (June 1998). "Safety of trovafloxacin in treatment of lower respiratory tract infections". European Journal of Clinical Microbiology & Infectious Diseases. 17 (6): 454–458. doi:10.1007/bf01691582. PMID 9758292. S2CID 1325773.

theguardian.com

washingtonpost.com